XBP1 and neoplasm: Similarly, decreases of other UPR mediators; XBP1, IRE1 and PERK, through knock-downs, knock-outs and null mutations in a range of cancer models result in decreased tumour size and reduced angiogenesis [53,54,55,56,57].